# Fount Bio, Inc.

> Fount Bio is a Somerville, Massachusetts life-science company that builds long-lasting hyaluronic acid (HA) matrices directly inside living tissue. Its proprietary Flī-HA platform uses Nobel-Prize-winning bioorthogonal (click) chemistry to deliver HA building blocks that self-assemble in situ into a biostable, high-molecular-weight matrix - overcoming the delivery and degradation barriers that have long forced HA to be injected as pre-formed filler. The lead product, Flī-Derm, is a needle-free liquid for aesthetic dermatology that reduced fine lines and wrinkles in a blinded clinical study and won IMCAS 2024's Innovation of the Year. The tunable platform extends toward ophthalmology, joints, mucosal tissue and women's health.

- **Founded:** 2018
- **Headquarters:** Somerville, Massachusetts, United States
- **Founders:** Doug Levinson (Co-Founder & CEO), Samir Mitragotri (Co-Founder & Senior Scientific Advisor)
- **Team size:** ~9 employees
- **Products:** Flī-HA Platform, Flī-Derm, Pipeline programs
- **Notable:** Won first place in the Innovation Tank and IMCAS World Congress 2024 'Innovation of the Year' award in Paris (Feb 2024) for Flī-Derm., Demonstrated significant reduction of fine lines and wrinkles for Flī-Derm in a blinded clinical study with strong safety and tolerability., Built the first platform designed to construct a biostable HA matrix in situ using bioorthogonal chemistry.

## Products & services

- **Flī-HA Platform** — A proprietary bioorthogonal (click) chemistry platform that delivers hyaluronic acid building blocks into target tissue, where they rapidly transform in situ into a high-molecular-weight, biostable HA matrix. Highly tunable so delivery can be tailored per application.
- **Flī-Derm** — Lead aesthetic-dermatology product: a needle-free liquid formulation with gentle assisted delivery that builds durable HA within the dermis. In a blinded clinical study it significantly reduced fine lines and wrinkles versus control, with strong safety and tolerability.
- **Pipeline programs** — Earlier-stage programs applying the Flī-HA platform to ophthalmology, women's health, joints and mucosal tissues.

## Achievements

- Won first place in the Innovation Tank and IMCAS World Congress 2024 'Innovation of the Year' award in Paris (Feb 2024) for Flī-Derm.
- Demonstrated significant reduction of fine lines and wrinkles for Flī-Derm in a blinded clinical study with strong safety and tolerability.
- Built the first platform designed to construct a biostable HA matrix in situ using bioorthogonal chemistry.
- Closed a Series A led by Morningside Ventures to advance the platform to clinical proof of concept.

## Latest updates

- **2024-02** — Flī-Derm named Innovation of the Year at IMCAS World Congress 2024 in Paris after winning the Innovation Tank competition.
- **2024-01** — Reported blinded clinical study results showing Flī-Derm significantly reduced fine lines and wrinkles with strong safety and tolerability.
- **2021-07** — Closed Series A financing led by Morningside Ventures to advance the Flī-HA platform to clinical proof of concept.

## Links

- Website: https://fountbio.com
- LinkedIn: https://www.linkedin.com/company/fount-bio-inc

---

Profile page: https://yespress.io/fount-bio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-21